TME Pharma announces results of successful capital increase with preferential subscription rights for €2.7 million
Transaction raised the full amount of €2.7 million leading to the issuance of 10.8 million new shares Strong demand prim…
Transaction raised the full amount of €2.7 million leading to the issuance of 10.8 million new shares Strong demand prim…
This information is not intended for residents of the United Kingdom, United States, Australia, Canada or Japan. See Ann…
Guaranteed portion of the transaction will extend cash runway past regulatory milestones in Q1-2024 The financial visibi…
Substantially improved survival and progression-free survival under NOX-A12 treatment combination compared to matched st…
Survival data from NOX-A12 GLORIA Phase 1/2 trial in brain cancer continue to improve and have already surpassed all rel…
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatm…
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatm…
Percentage of patients alive 18 months after start of therapy 10-fold higher than standard of care reference cohort Medi…
NOX-A12, in combination with radiotherapy and bevacizumab, outperforms all relevant competing benchmark therapies in dev…
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatm…